Novo Nordisk AS (NONOF)
71.25
+5.31
(+8.05%)
USD |
OTCM |
May 27, 16:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 316.59B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -46.05% |
| Valuation | |
| PE Ratio | 21.10 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.285 |
| Price to Book Value | 15.75 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.143 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.857 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 60.42% |
Profile
Edit
| With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
| URL | https://www.novonordisk.com |
| Investor Relations URL | https://www.novonordisk.com/investors.html |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Aug. 06, 2025 |
| Last Earnings Release | May. 07, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 28, 2025 |
Ratings
Profile
Edit
| With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
| URL | https://www.novonordisk.com |
| Investor Relations URL | https://www.novonordisk.com/investors.html |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Aug. 06, 2025 |
| Last Earnings Release | May. 07, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 28, 2025 |